Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial

Akira Yokomizo1,2 | Hirofumi Koga1,2 | Kazuto Ito3 | Yutaka Takezawa4 | Motokiyo Komiyama5 | Kazuo Nishimura6 | Junji Yonese7 | Katsuyoshi Hashine8 | Naoya Masumori9 | Gaku Arai10 | Shiro Saito11 | Mitsuru Shinohara12 | Nobuaki Shimizu13 | Atsushi Yamauchi14 | Takefumi Satoh15 | Tatsuo Tochigi16 | Mikio Kobayashi14 | Hiroyuki Fujimoto5 | Ken-ichi Kakimoto6 | Iwao Fukui7 | Taji Tsukamoto17 | Miwako Nozaki18 | Katsuyuki Karasawa19 | Masaru Hasumi13 | Mikinobu Ohnishi14 | Hiromichi Ishiyama20 | Masaaki Kuwahara21 | Masaoki Harada22 | Yasuo Ohashi23 | Toshihiko Kotake24 | Tadao Kakizoe25 | Kazuhiro Suzuki3 | Seiji Naito1 | Hidetoshi Yamanaka26 | National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators

1Department of Urology, Graduate School of Medicine, Kyusyu University, Fukuoka, Japan
2Department of Urology, Harasanshin Hospital, Fukuoka, Japan
3Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan
4Department of Urology, Isesaki Municipal Hospital, Isesaki, Japan
5Department of Urology, National Cancer Center Hospital, Tokyo, Japan
6Department of Urology, Osaka International Cancer Institute, Osaka, Japan
7Department of Urology, Cancer Institute Hospital, Tokyo, Japan
8Department of Urology, Shikoku Cancer Center Hospital, Matsuyama, Japan
9Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan
10Department of Urology, Dokkyo University Koshigaya Hospital, Koshigaya, Japan
11Department of Urology, Tokyo Medical Center, Tokyo, Japan
12Department of Urology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
13Department of Urology, Gunma Cancer Center Hospital, Ohta, Japan
14Department of Urology, Ibaraki Prefectural Central Hospital, Kasama, Japan
15Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan
16Department of Urology, Miyagi Cancer Center, Natori, Japan

All authors are members of The National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer.

†The National Research Project Investigators are listed in the Appendix section.

Clinical Trial Registry: This study was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN-CTR) within the Japan Primary Registries Network (JPRN) (Ref. Number UMIN000017242) before the data analysis.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
17 Sapporo Medical University School of Medicine, Sapporo, Japan
18 Department of Radiation Oncology, Dokkyo University Koshigaya Hospital, Koshigaya, Japan
19 Department of Radiation Oncology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
20 Department of Radiation and Radiation Oncology, Kitasato University, Sagamihara, Japan
21 Sendai Jin-hinyokika, Sendai, Japan
22 Kanagawa Cancer Center, Yokohama, Japan
23 University of Tokyo, Tokyo, Japan
24 Kotake Clinic, Osaka, Japan
25 President, Japan Cancer Society, Tokyo, Japan
26 Institute for Preventive Medicine, Kurosawa Hospital, Takasaki, Japan

Correspondence
Akira Yokomizo, Director, Department of Urology, Harasanshin Hospital, Taihakumachi 1-8, Hakata-ku, Fukuoka 812-0033 Japan.
E-mail: yokoa@harasanshin.or.jp

Funding information
Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare in Japan: Grant number: 12–14 (from April 2000 to March 2005), Grant number 15S-2 (from April 2005 to March 2006), Grant number 18S-2 (from April 2006 to March 2009), Grant number 21SS-2 (from April 2009 to March 2011), and Grant number 23- A- 14 (from April 2011 to March 2013).

Abstract
Background: We evaluated patient-reported outcomes (PRO) during neoadjuvant androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) followed by either adjuvant continuous ADT (CADT) or intermittent ADT (IADT) for patients with locally advanced prostate cancer (Pca).

Methods: A multicenter, randomized phase III trial enrolled 303 patients with locally advanced Pca. The patients were treated with 6 months (M) of ADT followed by 72 Gy of EBRT, and were randomly assigned to CADT or IADT after 14 M. The PROs were evaluated at six points: baseline, 6 M, 8 M, 14 M, 20 M, and 38 M using FACT-P questionnaires and EPIC urinary, bowel, and sexual bother subscales.

Results: The FACT-P total scores were significantly better ($p < 0.05$) in IADT versus CADT at 20 M (121.6 vs. 115.4) and at 38 M (119.9 vs. 115.2). The physical well-being scores (PWB) were significantly better ($p < 0.05$) in IADT versus CADT at 38 M (25.4 vs. 24.0). The functional scores were significantly better in IADT than those in CADT at 14 M (20.2 vs. 18.7, $p < 0.05$) and at 20 M (21.0 vs. 18.9, $p < 0.05$).

Conclusion: The PRO was significantly favorable in IADT on FACT-P total score at 20 M and 38 M, PWB and functional scores at 38 M.

KEYWORDS
external beam radiation therapy, intermittent androgen deprivation therapy, prostate cancer, QOL, neoadjuvant

1 | INTRODUCTION

The incidence of Pca has increased not only in developed Western countries, but also in developed Asian countries. Locally advanced Pca is generally treated with high-dose radiation therapy and long-term ADT or radical prostatectomy with extended lymph node dissection. Long-term ADT can lead to adverse effects such as hot flashes, night sweats, erectile dysfunction, decreased libido, fatigue, depression, gynecomastia, decreased hemoglobin levels, changes in fat and lean body mass, changes in plasma lipoproteins, increased insulin levels, and osteoporosis. A systematic review of randomized trials that compared CADT versus IADT concluded that IADT has fewer sexual side effects and allows more physical activity, leading to a better QOL, and is also more cost-effective. This clinical trial compared the outcome of IADT with that of continuous adjuvant ADT after EBRT in patients with locally advanced Pca (cT3-4 N0 M0). Patient-reported outcomes (PRO) are often assessed through randomized controlled trials (RCTs) that include HRQOL and other measures of QOL. The findings are used to improve patient-centered care and to make decisions regarding clinical and medical policies.

2 | PATIENTS AND METHODS

2.1 | Study design and participants

The details of the study protocol, baseline data, and endpoint results have been described previously. Briefly, 303 patients...
less than 80 years of age with locally advanced Pca diagnosed by MRI (cT3/4N0 M0) were enrolled and 280 patients were randomized after 6 months of induction with ADT using a luteinizing hormone agonist if the prostate-specific antigen level was <10 ng/ml. All participants underwent 72 Gy in 36 fractions of EBRT to the prostate by three-dimensional conformal radiotherapy combined with 2 months of concomitant ADT and 6 months of adjuvant ADT (Figure 1). The irradiation to the whole pelvis was not performed. The 280 participants were divided randomly into two arms at a 1:1 ratio to receive either long-term adjuvant ADT for 5 years (arm 1) or intermittent ADT (arm 2) that continued as 6 months of adjuvant ADT, after completing EBRT. Patients in the intermittent ADT group resumed hormonal therapy if their PSA level was ≥5 ng/ml or if they suffered clinical recurrence. The primary endpoint was the biochemical relapse-free survival (bRFS). The median follow-up duration after randomization was 8.2 years.

The patient-reported outcome (PRO) was evaluated using a Japanese version of Expanded Prostate Index Composite (EPIC) and a FACT-P questionnaire, both of which are frequently used and validated to assess the QOL of men with clinically localized and advanced Pca. In this study, selected questionnaire on urinary, bowel and sexual “bother” was adopted from EPIC, and they consist of 5-point subscales (the actual questionnaires and questions are shown in Data S1). The FACT-P consists of a FACT-general questionnaire (FACT-G) and a prostate cancer subscale (PCS). The FACT-G, a 29-item self-reporting questionnaire that measures general QOL in cancer patients, consists of four subscales of well-being, physical, functional, social/family, and emotional, whereas the PCS is a 12-item scale specifically designed to measure the prostate-specific QOL. The FACT-P is calculated by adding the four FACT-G scores and the PCS score to yield a composite QOL score; a higher overall score indicates a better QOL. All the patients in this analysis completed Japanese versions of FACT-P questionnaires and provided scores for selected questionnaire on urinary, bowel, and sexual bother. According to the “FACT Administration and Scoring Guidelines,” when there are missing data, prorating by subscale is acceptable as long as more than 50% of the items were answered. The FACT scale is considered to be an acceptable indicator of patient quality of life as long as overall item response rate is greater than 80%. In addition, a total score should only be calculated if all of the component subscales have valid scores. The number of the analyzed patients in Figure 1 shows the number of patients who met all these conditions.

### 3 | PROCEDURES

#### 3.1 | Statistical analysis

Statistical analyses were performed according to the intention-to-treat principle, using an LSMEANS statement

![Figure 1](image_url)
that compared the QOL at baseline with that at several time points. The Wilcoxon signed-rank test was adapted to compare the results of CADT with those of IADT. Statistical analyses were independently calculated at STATCOM Co., Ltd. A likelihood-ratio test evaluated the evidence against a null hypothesis of equal mean response over 6 years of follow-up across the three groups. Two-level random effects models were used to accommodate the correlation between the repeated assessments for each man. Two-level linear models (also known as variance component models) were used for continuous measures, and two-level logistic models were used for binary measures; normal random effects distributions were used in both the linear and logistic models. All models included as covariates variables that were used for stratification or minimization in the randomization process: age and PSA level at baseline (continuous variables) and Gleason score and study center (dummy variables). Although we had planned to include baseline measures as covariates, we did not include them because the EPIC instrument and the ICIQ were not available for men who were recruited early in the trial. No meaningful differences in patient-reported outcome measures across groups were observed at baseline. We defined the minimal clinically important difference (MCID) as half the standard deviation of the baseline score for each domain as previously reported on EPIC. The sponsors of the study had no role in the study design, data collection, data analysis, data interpretation, or preparation of the manuscript. The corresponding author had full access to all study data that were submitted for publication in the final manuscript. This trial began in 2000 and was registered as a cancer research study (Ref. Number UMIN000017242) supported by University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN-CTR) within the Japan Primary Registries Network (JPRN) before recruitment of the first participant. The protocol was approved by each Institutional Review Board prior to commencing this study.

4 | RESULTS

Of the 280 initially enrolled patients, 228 patients completed the treatment protocol. Regarding completion of the FACT questionnaire, 270 patients complied at baseline, 258 (96%)

![Figure 2](image_url)
at 6 M, 254 (94%) at 8 M, 226 (84%) at 14 M, 201 (74%) at 20 M, and 192 (71%) at 38 M (Figure 1), reflecting a very high PRO compliance rate. We defined the MCID as half the standard deviation (SD) of the baseline score for each domain, only clinically significant changes will be described on the result of QOL analysis. The obtained average score of baseline and SD was described in Table S1.

4.1 | Neoadjuvant ADT

In the neoadjuvant ADT periods, FACT-P total score improved at 6 M, but it was not clinically significant from the baseline. While, urinary bother score improve from the baseline (2.7–3.1, \( p < 0.01 \), Figure 2A), there was no change in bowel and bother score (3.3–3.4, Figure 2B), and worsened in sexual bother score (3.2–2.8, clinically insignificant, Figure 2C). In this study, urinary, bowel, and sexual “bother” was adopted from EPIC.

4.2 | Radiation

If we look at the effects of radiation, the FACT-P total score decreased at 6 M (119.7–112.5) and recovered to baseline at 14 M (117.5), but they were not clinically significant (Figure 2D). The urinary bother scores worsened dramatically just after EBRT at 8 M (2.04, \( p < 0.01 \) comparing to 6 M (3.11), Figure 2A), and significantly improved at 14 M (3.09, \( p < 0.01 \) comparing to 8 M, Figure 2A) through 38 M (3.24) same trends were observed in bowel bother score (Figure 2B). The sexual bother scores continuously worsened after ADT, clinically significant differences were observed after EBRT (8 M) (2.0) comparing with those in baseline (2.7) and did not recovered during protocol treatment (Figure 2C). The physical well-being (PWB) of FACT-G significantly worsened after EBRT (24.7 at 6 M and 22.9 at 8 M, \( p < 0.05 \)) but recovered to baseline from 14 M (24.9) through 38 M (25.1) (Figure 3A). The social family score of FACT-G was stable (21.6 at 6 M and 21.7 at 8 M, Figure 3B) and the emotional score of FACT-G kept better trend (18.6 at 6 M and 18.2 at 8 M) (Figure 3C).

4.3 | Comparison of CADT and IADT in adjuvant ADT

In adjuvant ADT phase, characteristic results were obtained in comparison of IADT and CADT. The FACT-P total score

![Figure 3](image.png)

**Figure 3** (A) Shown are the average number of scores in (A) Physical well-being score, (B) Social/family subscale, (C) Emotional subscale, and (D) Functional score of FACT-G. The actual questions are listed in the Data S1. The higher number indicates better QOL. The error bar represent standard error. A clinically significant difference \( *p <0.05 \) from baseline, double-headed arrow, a clinically significant difference between the IADT and CADT groups.
was significantly improved in IADT, whereas it kept worse in CADT (121.6 vs. 115.4 at 20 M, p<0.05 and 119.9 vs. 115.2 at 38 M, p<0.05), resulting in they were clinically significantly different (Figure 2D). In IADT, PWB score of FACT-G were no change at 20 M (24.9) and got better at 38 M (25.4), whereas PWB of FACT-G kept getting worse during CADT (24.8 at 14 M, 24.5 at 20 M and 24.0 at 38 M), the differences were statistically significant between IADT and CADT at 38 M (p<0.05, Figure 3A). The functional subscale of FACT-G score tended to decrease in CADT (19.1 at 8 M, 18.7 at 14 M, 18.9 at 20 M, and 19.4 at 38 M) (Figure 3D), but recovered and showed statistically significant better score in IADT at 14 M (20.2, p<0.05 comparing to CADT) and 20 M (21.0, p<0.05 comparing to CADT) than those in CADT (Figure 3D). In comparison of CADT and IADT, there was a better trend in social family subscale (Figure 3B) and emotional subscale of FACT-G (Figure 3C), but it was not significant.

In summary of comparison of CADT and IADT, clinically significant better outcomes in IADT were observed in PWB at 38 M (Figure 3A), in functional subscale of FACT-G at 14 M and 20 M (Figure 3D), and FACT-P score at 20 M and 38 M (Figure 2D). To summarize the whole changes during the protocol treatment, the social/family subscale score of FACT-G continuously decreased as the treatment proceed (Figure 3B), but they were not clinically significant. While the emotional subscale scores of FACT-G consistently improved during the study and clinically significantly improved at 20 M (19.0) from the baseline (16.9, p<0.05, Figure 3C).

In Figure 4, the transition of the ratio in bother score over time in A) urinary, B) bowel, and C) sexual score are shown. The transition of the average value of each QOL scale shown in Figure 2 can be easily understood even with the transition of percentage of each score (Figure 4).

A total of 101 (72.7%) of the 139 patients in arm 2 did not undergo salvage ADT during the IADT phase, and among the 101 patients, 97 patients had no PSA recurrence or clinical recurrence, and 4 had PSA recurrence and did not proceed the protocol treatment. Overall durations of ADT (10 person-years) during the observation 346 period were 6.50 and 2.47 years in trial arms 1 and 2, respectively.

![Figure 4](image-url)
5 | DISCUSSION

Our data demonstrated an interesting QOL trend and advantage in adjuvant IADT during hormone-radiation therapy for locally advanced Pca. In this study, clinically significant better outcomes in IADT were observed in PWB at 38 M (Figure 3A), in functional subscale at 14 M and 20 M (Figure 3D), and FACT-P score at 20 M and 38 M (Figure 2D). Several RCTs had been to attempt to quantify the health-related QOL benefit inherent in IADT of Pca treatment, but so far as we know, there had been no RCTs on QOL analysis in adjuvant hormone therapy setting after EBRT in locally advanced Pca. Shevach J et al., summarized the QoL difference between CADT and IADT in 10 RCTs in his review article. They mentioned that various domains—usually related to physical or sexual functioning—within the questionnaire favored those in the IADT with statistical significance in several trials, but the differences were either short lived or clinically insignificant, or their magnitude lacked consistency across studies. The randomized Finn Prostate Study VII by Salonen et al. compared the QOL of patients with advanced Pca who underwent IADT or CADT; it revealed that IADT allowed significantly better QOL due to better physical capacity, increased activity, and improved sexual function. While, Verhagen et al. demonstrated limited improvement in QOL scores for patients receiving IADT in physical (88 vs. 87.1 out of 100; p = 0.003) and emotional (92.5 vs. 91.5 out of 100; p < 0.001) functioning and QOL scores in cognitive functioning were better in the group receiving CAD (88.4 vs. 83.4; p < 0.001). In this study, patients who underwent IADT had a significantly better QOL, as indicated by a higher FACT-P total score (Figure 2D), as well as higher physical well-being and functional scores (Figure 3A,D). Since the QOL analysis is greatly influenced by the stage of the patient, the timing of starting IADT, and the kinds of intervention, it is important to refer to each result in each RCT design.

Only a few prospective randomized trials have examined the change in QOL for Pca patients undergoing hormone-radiation therapy. The recent PROs from the Prostate Testing for Cancer and Treatment (ProtecT) randomized controlled trial were used to compare the clinical outcomes and QOL for patients with low-risk localized Pca who underwent active monitoring, radical prostatectomy, or radiotherapy. We also refer CHHiP phase III trial that compared the QOL of patients undergoing hypofractionated EBRT versus conventional fractionated EBRT for comparison. In this study, the urinary function and bother scores significantly improved after neoadjuvant ADT (6 M). Axsrona et al., reported that ADT by degarelix or goserelin improved International Prostate Symptom Score (IPSS) and the Benign Prostate Hyperplasia Impact Index accompanied by prostate volume reduction. The same mechanism could have been affected in this study. Subsequently, urinary bother score got worse dramatically just after EBRT (8 M), improved significantly at 14 M through 38 M comparing from those in baseline (Figure 2A). These results were also observed in radiotherapy cohort in ProtecT trial. The bowel subscale score was not affected by neoadjuvant ADT but dramatically impaired after EBRT (8 M) and recovered by 14 M in our study (Figure 2B). Similar trends were observed in a CHHiP phase III trial. The CHHiP trial revealed no significant dose-dependent differences in the EPIC bowel score but the score did quickly worse 10 weeks after initiating EBRT, recovered at 6 M, and kept slightly worse condition until 24 M. In ProtecT, bowel score rapidly spoiled at 6 M and quickly recovered similarly to that of the active monitoring group, but remained lower over time. Physicians must be mindful of the intestinal health of Pca patients undergoing EBRT. In sexual subscale scores continuously got worse after ADT and EBRT, and it had a tendency to improve at 38 M in IADT group comparing to those in CADT (Figure 2C). In ProtecT trial, it was worst at 6 months, but then recovered somewhat and was stable thereafter, which was different from our study. We estimate the difference was due to the duration of ADT. The physical well-being scores significantly worsened after EBRT but recovered by 14 M (Figure 3A). The emotional score continuously impaired (Figure 3B), but the emotional score continuously improved (Figure 3C). We estimate the reason of this trend as follows: The patients felt the most anxious at diagnosis because they had recently been informed that locally advanced Pca could be fatal. At that time, family and friends tried to support them as much as possible, which increased patients’ emotional scores. Throughout treatment, the PSA level decreased for most patients and their urinary function improved after ADT and quickly recovered after EBRT, which contributed to their better emotional health. As the patient’s condition improves, the worry of family and his friends decreased, which reflected to a decreasing trend in social/family score.

This study contains several limitations. First, as in any randomized, controlled trial, patients were selected based on specific criteria and the results may not be generalizable to other patient cohorts. Second, the eligibility criteria were set in this study, but detailed comorbidity data were not collected in this study. Therefore, these results may not apply to patients with any complications.

In primary endpoint analysis, the 5-year bRFS rates were 84.8% and 82.8% for arm 1 and arm 2, respectively (hazard ratio [HR], 1.132; 95% confidence interval, 0.744–1.722). The upper limit of hazard ratio of non-inferiority of IADT compared to CADT was set as 1.5, the oncological outcome of this study did not confirm the non-inferiority of adjuvant IADT compared to CAD. If non-inferiority of adjuvant IADT compared to CADT is confirmed, adjuvant IADT had become a standard treatment because it has the advantage in
QOL as well as the lower medical cost. Additionally, the superiority of either arm was not confirmed, and the Kaplan–Meier curves of progression-free survival and overall survival seemed to overlap. Even though the clinical decision is left to the physicians, physicians should offer adjuvant IADT as a treatment option for patients with locally advanced Pca based on our results.

PRIOR PRESENTATION

Presented in part at the Annual European Association of Urology Congress, Munich, Germany, March 11–15, 2016.

ACKNOWLEDGMENTS

Thanks to all investigators who contributed to the study, The National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer.

CONFLICT OF INTEREST

Kazuto Ito received honoraria from Takeda Pharmaceutical Company Limited, AstraZeneca, Astellas, and ASKA Pharmaceutical Company Limited. Mikio Kobayashi has no disclosures or potential conflict of interest to report. Motokiyo Komiyama has no disclosures or potential conflict of interest to report. Seiji Naito received honoraria from Takeda Pharmaceutical Company Limited, AstraZeneca, and Astellas. Kazuo Nishimura received honoraria from Takeda Pharmaceutical Company Limited, AstraZeneca, Astellas, and ASKA Pharmaceutical Company Limited. Junji Yonese received honoraria from Takeda Pharmaceutical Company Limited, AstraZeneca, and Astellas. Katsuyoshi Hashine received honoraria from Takeda Pharmaceutical Company Limited, AstraZeneca, and Astellas. Shiro Saito received honoraria from Takeda Pharmaceutical Company Limited, AstraZeneca, and Astellas and received grant support from Takeda Pharmaceutical Company Limited, AstraZeneca, and Astellas. Gaku Arai has no disclosures or potential conflict of interest to report. Mitsuru Shinohara received honoraria from Astellas. Naoya Masumori received honoraria from Astellas, AstraZeneca, Nippon Shinyaku, Asahi-Kasei Pharma, Daichi-Sankyo, GSK, Takeda Pharma, and Kissei and received grant support from Astellas, Takeda Pharma, Shionogi, and Green Peptide. Nobuaki Shimizu received honoraria from Takeda Pharmaceutical Company Limited, AstraZeneca, and Astellas. Takefumi Satoh has no disclosures or potential conflict of interest to report. Akira Yokomizo received honoraria from Astellas Pharma Inc, AstraZeneca, Bayer Yakuhin, Ltd, Janssen Pharmaceutical K.K., Sanofi Genzyme and Takeda Pharmaceutical Company Ltd. Ken-ichi Kakimoto has no disclosures or potential conflict of interest to report. Iwao Fukui has no disclosures or potential conflict of interest to report. Katsuyuki Karasawa has no disclosures or potential conflict of interest to report. Taiji Tsukamoto received honoraria from Astellas. Miwako Nozaki has no disclosures or potential conflict of interest to report. Masaru Hasumi received honoraria from Takeda Pharmaceutical Company Limited and AstraZeneca. Hiromichi Ishiyama has no disclosures or potential conflict of interest to report. Mikinobu Ohtani has no disclosures or potential conflict of interest to report. Masaaki Kuwahara has no disclosures or potential conflict of interest to report. Masaoki Harada has no disclosures or potential conflict of interest to report. Yasuo Ohashi has no disclosures or potential conflict of interest to report. Toshihiko Kotake has no disclosures or potential conflict of interest to report. Tadao Kakizoe has no disclosures or potential conflict of interest to report. Kazuhiro Suzuki received honoraria from Takeda Pharmaceutical Company Limited, Astellas, and AstraZeneca and received grant support from Takeda Pharmaceutical Company Limited and Astellas. Hidetoshi Yamanaka has no disclosures or potential conflict of interest to report.

AUTHOR CONTRIBUTIONS

Yokomizo A, Koga H, Ito K, Takezawa Y, Naito S, Hashine K, Sato S, Shinohara M, Masumori N, Shimizu N, Tochigi T, Kobayashi M, Fujimoto H, Fukui I, Karasawa K, Tsukamoto T, Ohtani M, Kuwahara M, Harada M, Ohashi Y, Kotake T, Kakizoe T, Suzuki K, and Yamanaka H designed the study. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Naito S, Nishimura K, Yonose J, Hashine K, Saito S, Araig G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Kobayashi M, Fujimoto H, Yokomizo A, Kakimoto K, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, and Ohashi Y did the study. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Naito S, Nishimura K, Yonose J, Hashine K, Saito S, Araig G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Kobayashi M, Fujimoto H, Yokomizo A, Kakimoto K, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, and Ohashi Y did the study. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Naito S, Nishimura K, Yonose J, Hashine K, Saito S, Araig G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Kobayashi M, Fujimoto H, Yokomizo A, Kakimoto K, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, and Ohashi Y did the study. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Naito S, Nishimura K, Yonose J, Hashine K, Saito S, Araig G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Kobayashi M, Fujimoto H, Yokomizo A, Kakimoto K, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, and Ohashi Y did the study. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Naito S, Nishimura K, Yonose J, Hashine K, Saito S, Araig G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Kobayashi M, Fujimoto H, Yokomizo A, Kakimoto K, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, and Ohashi Y did the study. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Naito S, Nishimura K, Yonose J, Hashine K, Saito S, Araig G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Kobayashi M, Fujimoto H, Yokomizo A, Kakimoto K, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, and Ohashi Y did the study. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Naito S, Nishimura K, Yonose J, Hashine K, Saito S, Araig G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Kobayashi M, Fujimoto H, Yokomizo A, Kakimoto K, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, and Ohashi Y did the study. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Naito S, Nishimura K, Yonose J, Hashine K, Saito S, Araig G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Kobayashi M, Fujimoto H, Yokomizo A, Kakimoto K, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, and Ohashi Y did the study. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Naito S, Nishimura K, Yonose J, Hashine K, Saito S, Araig G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Kobayashi M, Fujimoto H, Yokomizo A, Kakimoto K, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, and Ohashi Y did the study. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Naito S, Nishimura K, Yonose J, Hashine K, Saito S, Araig G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Kobayashi M, Fujimoto H, Yokomizo A, Kakimoto K, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, and Ohashi Y did the study.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES

1. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. *Eur Urol*. 2012;61:1079-1092.

2. Ito K. Prostate cancer in Asian men. *Nat Rev Urol*. 2014;11:197-212.

3. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol*. 2017;71:618-629.

4. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. *Cancer*. 2009;115:2388-2399.

5. Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with androgen deprivation: a systematic review of randomized trials. *J Clin Oncol*. 2013;31:2029-2036.

6. Lipscomb J, Reeve BB, Clauser SB, et al. Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. *J Clin Oncol*. 2007;25:5133-5140.

7. Ito K, Kobayashi M, Komiyama M, et al. Oncological outcomes for patients with locally advanced prostate cancer treated with neo-adjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial. *Cancer*. 2020;126:3961-3971.

8. Kakehi Y, Takegami M, Suzukamo Y, et al. Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite. *J Urol*. 2007;177:1856-1861.

9. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. *Urology*. 1997;50:920-928.

10. Hamoen EH, De Rooij M, Witjes JA, Barentsz JO, Rovers MM. Measuring health-related quality of life in men with prostate cancer: a systematic review of the most used questionnaires and their validity. *Urol Oncol*. 2015;33(6):61-80.

11. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. *Urology*. 2000;56:899-905.

12. Maruyama Y, Sadahira T, Araki M, et al. Comparison of longitudinal health-related quality-of-life outcomes between anterior and posterior surgical approaches to robot-assisted radical prostatectomy. *J Robot Surg*. 2020;14:255-260.

13. Shevach J, Sydes MR, Hussain M. Revisiting Intermittent Therapy in Metastatic Prostate Cancer: can Less be More in the "New World Order"? *Eur Urol Focus*. 2019;5:125-133.

14. Salonen AJ, Taari K, Ala-Opas M, et al. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. *J Urol*. 2012;187:2074-2081.

15. Verhagen PC, Wildhagen MF, Verkerk AM, et al. Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial. *World J Urol*. 2014;32:1287-1294.

16. Salonen AJ, Taari K, Ala-Opas M, et al. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects. *Eur Urol*. 2013;63:111-120.

17. Donovan JL, Hamdy FC, Lane JA, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. *N Engl J Med*. 2016;375:1425-1437.

18. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. *N Engl J Med*. 2016;375:1415-1424.

19. Wilkins A, Mossop H, Syndikus I, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. *Lancet Oncol*. 2015;16:1605-1616.

20. Axcrona K, Aaltomaa S, da Silva CM, et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. *BJU Int*. 2012;110:1721-1728.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Yokomizo A, Koga H, Ito K, et al. Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial. *Cancer Med*. 2021;10:3240–3248. [https://doi.org/10.1002/cam4.3895](https://doi.org/10.1002/cam4.3895)

APPENDIX

The national research project on endocrine-radiation combination therapy for locally advanced prostate cancer investigators: *Central office staff: Gunma, Japan—Atsuko Ohyama; Central Clinical Trial Unit Director: Tokyo, Japan—Yasuo Ohashi; Central Pathological Office Director: Kanagawa, Japan—Masaoki Harada; Collaborators of the study: Japan—T Yamamoto, M Miyakubo, and Y Fujizuka (Gunma University, Maebashi); T Akimoto (National Cancer Center Hospital East, Kashiwa); N Mitsuhashi (Tokyo Women's Medical University, Tokyo); H Ishikawa (University of Tsukuba, Tsukuba); N Matsuoka (Misato central hospital, Misato); M Sumi (The Cancer Institute Hospital of JFCR, Tokyo); Y Ito (National Cancer Center Hospital, Tokyo); T Hamano (Takasaki Medical Center, Takasaki), K Tabata, H Tsumura, M Iwamura, S Komori, and K Hayakawa (Kitasato University School of Medicine, Sagamihara); and M Kitano (National Hospital Organization Sagamihara National Hospital, Sagamihara).*